Answers are grounded in this paper and cite their sources.
In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to encouraging pathological response rates in both cohorts, and sustained circulating tumor DNA negativity throughout neoadjuvant therapy may be predictive of response.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: